Vifor Pharma Group
- Business Wire
93rd Vifor Pharma Group Annual General Meeting
Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg…
Read More » - Business Wire
First patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatment
CARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or…
Read More » - Business Wire
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the…
Read More » - Business
Vifor Pharma to propose Dr Alexandre LeBeaut as Board member
St. Gallen, Switzerland: Dr Alexandre LeBeaut to be proposed to Annual General Meeting for appointment to Board Dr Gianni Zampieri…
Read More » - Business
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Bad Homburg, Germany & St. Gallen, Switzerland: Veltassa® is a well-tolerated1 and effective2 oral calcium potassium binder for the treatment of hyperkalemia supported…
Read More » - Business
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
St. Gallen, Switzerland & Uniondale, N.Y., United States: Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is…
Read More » - Business
Vifor Pharma Group Announces Successful Sale of OM Pharma
St. Gallen, Switzerland: Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF…
Read More »